150 related articles for article (PubMed ID: 22922887)
1. Prognostic significance of neuronal marker expression in glioblastomas.
Lee KH; Kang KJ; Moon KS; Jung TY; Jung S; Kim JH; Kim HS; Lee MC
Childs Nerv Syst; 2012 Nov; 28(11):1879-86. PubMed ID: 22922887
[TBL] [Abstract][Full Text] [Related]
2. Expression of diagnostic neuronal markers and outcome in glioblastoma.
Donev K; Scheithauer BW; Rodriguez FJ; Jenkins S
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):411-21. PubMed ID: 20298476
[TBL] [Abstract][Full Text] [Related]
3. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas.
Kim KJ; Lee KH; Kim HS; Moon KS; Jung TY; Jung S; Lee MC
Neuropathology; 2011 Oct; 31(5):494-502. PubMed ID: 21269333
[TBL] [Abstract][Full Text] [Related]
4. Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide.
Yan T; Skaftnesmo KO; Leiss L; Sleire L; Wang J; Li X; Enger PØ
BMC Cancer; 2011 Dec; 11():524. PubMed ID: 22185371
[TBL] [Abstract][Full Text] [Related]
5. New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases.
Varlet P; Soni D; Miquel C; Roux FX; Meder JF; Chneiweiss H; Daumas-Duport C
Neurosurgery; 2004 Dec; 55(6):1377-91: discussion 1391-2. PubMed ID: 15574220
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma.
Tsidulko AY; Kazanskaya GM; Kostromskaya DV; Aidagulova SV; Kiselev RS; Volkov AM; Kobozev VV; Gaitan AS; Krivoshapkin AL; Grigorieva EV
Tumour Biol; 2017 Sep; 39(9):1010428317724282. PubMed ID: 28945172
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of tetraspanin CD151 in newly diagnosed glioblastomas.
Lee D; Suh YL; Park TI; Do IG; Seol HJ; Nam DH; Kim ST
J Surg Oncol; 2013 May; 107(6):646-52. PubMed ID: 22926763
[TBL] [Abstract][Full Text] [Related]
8. Negative prognostic effect of low nuclear GLI1 expression in glioblastomas.
Kim Y; Do IG; Hong M; Suh YL
J Neurooncol; 2017 May; 133(1):69-76. PubMed ID: 28417299
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Treatment Tolerance and Factors Associated with Overall Survival in Elderly Patients with Glioblastoma.
Zhang C; Wang X; Hao S; Su Z; Zhang P; Li Y; Song G; Yu L; Wang J; Ji N; Xie J; Gao Z
World Neurosurg; 2016 Nov; 95():77-84. PubMed ID: 27485530
[TBL] [Abstract][Full Text] [Related]
10. Stratification according to recursive partitioning analysis predicts outcome in newly diagnosed glioblastomas.
Yang F; Yang P; Zhang C; Wang Y; Zhang W; Hu H; Wang Z; Qiu X; Jiang T
Oncotarget; 2017 Jun; 8(26):42974-42982. PubMed ID: 28496000
[TBL] [Abstract][Full Text] [Related]
11. The hedgehog antagonist HHIP as a favorable prognosticator in glioblastoma.
Chang L; Zhang P; Zhao D; Liu H; Wang Q; Li C; Du W; Liu X; Zhang H; Zhang Z; Jiang C
Tumour Biol; 2016 Mar; 37(3):3979-86. PubMed ID: 26482617
[TBL] [Abstract][Full Text] [Related]
12. [Oligodendroglial and neuronal component in glioblastomas: possible relation with prognosis].
Pinto LW; Chimelli L
Arq Neuropsiquiatr; 2004 Dec; 62(4):1074-8. PubMed ID: 15608972
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
14. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
[TBL] [Abstract][Full Text] [Related]
15. Giant cell glioblastoma and pleomorphic xanthoastrocytoma show different immunohistochemical profiles for neuronal antigens and p53 but share reactivity for class III beta-tubulin.
Martinez-Diaz H; Kleinschmidt-DeMasters BK; Powell SZ; Yachnis AT
Arch Pathol Lab Med; 2003 Sep; 127(9):1187-91. PubMed ID: 12946225
[TBL] [Abstract][Full Text] [Related]
16. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme.
Olmez OF; Cubukcu E; Evrensel T; Kurt M; Avci N; Tolunay S; Bekar A; Deligonul A; Hartavi M; Alkis N; Manavoglu O
Clin Transl Oncol; 2014 Feb; 16(2):173-7. PubMed ID: 23740136
[TBL] [Abstract][Full Text] [Related]
17. O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma.
Sonoda Y; Yokosawa M; Saito R; Kanamori M; Yamashita Y; Kumabe T; Watanabe M; Tominaga T
Int J Clin Oncol; 2010 Aug; 15(4):352-8. PubMed ID: 20232102
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract][Full Text] [Related]
19. Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
Wen J; Chen W; Zhu Y; Zhang P
BMC Cancer; 2021 Jan; 21(1):81. PubMed ID: 33468109
[TBL] [Abstract][Full Text] [Related]
20. Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis.
Pallud J; Dezamis E; Audureau E; Devaux B; Souillard-Scemama R; Sanai N; Page P; Beuvon F; Koziak M; Oppenheim C; Dhermain F; Schlienger M; Meder JF; Roux FX; Varlet P
J Neurosurg; 2012 Sep; 117(3):476-85. PubMed ID: 22725988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
